09 Dec 2025
7m
ASH 2025: Corvus CEO Richard Miller believes that ITK inhibitors can have the same broad impact on T-cell diseases as BTK inhibitors have had on B-cell diseases - he would know
BiotechTV - News
Open in Podwise to generate AI notes
Sign in to process this episode and unlock summaries, transcripts, highlights and translations.
Shownotes are not generated by Podwise.